betway Kabi’s product portfolio comprises a comprehensive range of I.V. generic drugs, infusion therapies and clinical nutrition products as well as the devices for administering these products. In the field of biosimilars, betway Kabi focuses on autoimmune diseases and oncology. Within transfusion technology, betway Kabi offers products used in the collection and processing of blood and cell components, as well as in transfusion medicine and cell therapies.
With its corporate philosophy of "caring for life", the company is committed to putting essential medicines and technologies in the hands of people who help patients and finding the best answers to the challenges they face.
betway Kabi employs over 40,000 people worldwide. In 2020 the company reported sales of more than €6.9 billion. betway Kabi AG is a wholly owned subsidiary of the betway SE & Co. KGaA health care group.